This trial is active, not recruiting.

Condition diabetes insipidus
Treatment desmopressin
Sponsor National Center for Research Resources (NCRR)
Collaborator Northwestern University
Start date December 1995
Trial size 5 participants
Trial identifier NCT00004364, 199/11939, NU-570



I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Primary purpose screening

Eligibility Criteria

Male or female participants from 6 months up to 70 years old.

- Familial diabetes insipidus (DI) in atypical or novel form, e.g.: Dipsogenic DI Neurohypophyseal DI - Affected and unaffected members of kindreds eligible

Additional Information

Description PROTOCOL OUTLINE: Participants undergo a series of tests to determine the presence, absence, cause, natural history, clinical status, and mode of inheritance of their type of diabetes insipidus (DI). The studies include measurements of basal fluid intake and urine output, plasma vasopressin during standard fluid deprivation or waterload/saline infusion tests, and changes in water balance during a therapeutic trial of DDAVP. If clinically indicated, echocardiograms and assays of plasma catecholes and renin are also completed. Linkage analysis is performed for all participants; kindreds with the Marfan-like syndrome are also studied for the fibrillin-1 genotype. Participants determined to have DI are treated with desmopressin for 2 days.
Trial information was received from ClinicalTrials.gov and was last updated in February 2006.
Information provided to ClinicalTrials.gov by Office of Rare Diseases (ORD).